Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | MAOA | P21397 | 8/20 | 0.50 |
| ▸ | CALML3 | P27482 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594796 | 0.87 | MAOA (0.67) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6918139 | 0.85 | MAOB (0.53) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6917623 | 0.84 | F10 (0.46) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6916830 | 0.82 | MAOB (0.43) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6918940 | 0.81 | MAOB (0.57) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6914676 | 0.77 | MAOB (0.76) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL18410768 | 0.76 | MAOB (0.48) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL591439 | 0.76 | MAOB (0.53) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL591440 | 0.76 | MAOB (0.53) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6916833 | 0.76 | F10 (0.48) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743811-B2 | MICROBIOCIDES | PHARMACIA & UPJOHN COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20020169191-A1 | Oxazolidinone compounds and methods of preparation and use thereof | PHARMACIA & UPJOHN COMPANY (US) | 2002-11-14 | — | — | US | disclosed |
| US-6441005-B1 | BACTERICIDES, ANTIBIOTICS AND MICROBIOCIDES | PHARMACIA & UPJOHN COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1200416-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIINFECTIVES | Pharmacia & Upjohn Company (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009107-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIINFECTIVES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169191-A1 | Oxazolidinone compounds and methods of preparation and use thereof | OXA1L, PAM, DPM1 | MAOB 852/4885MAOA 968/4885CALML3 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.